51135-91-2

Basic information

• Product Name: 4-AMINO-1-INDANONE
• Synonyms: 4-AMINO-INDAN-1-ONE;4-AMINO-1-INDANONE;4-amino-2,3-dihydroinden-1-one;4-aminoindanone;4-amino-2,3-dihydro-1H-inden-1-one;1-Indanone, 4-aMino-
• CAS NO: 51135-91-2
• Molecular Formula: C₉H₉NO
• Molecular Weight: 147.17
• Mol File: 51135-91-2.mol

Chemical Properties

• Melting Point: 122-123 °C
• Boiling Point: 323.177 °C at 760 mmHg
• Flash Point: 149.252 °C
• Appearance: /
• Density: 1.255 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.65
• PKA: 3.20±0.20(Predicted)
• CAS DataBase Reference: 4-AMINO-1-INDANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-1-INDANONE(51135-91-2)
• EPA Substance Registry System: 4-AMINO-1-INDANONE(51135-91-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 51135-91-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-AMINO-1-INDANONE is used as a key intermediate in the synthesis of pharmaceuticals for its potential therapeutic effects in treating a range of diseases. Its unique structure allows for the development of new drugs with improved efficacy and safety profiles.
Used in Organic Synthesis:
In the field of organic synthesis, 4-AMINO-1-INDANONE is employed as a versatile building block, enabling the creation of a variety of complex organic molecules. Its reactivity and functional groups facilitate the formation of diverse chemical entities for use in various applications.
Used in Drug Discovery:
4-AMINO-1-INDANONE is utilized in drug discovery processes due to its potential pharmacological properties. Researchers explore its interactions with biological targets to identify new therapeutic agents that can address unmet medical needs.
Used in Chemical Research:
4-AMINO-1-INDANONE serves as a subject of chemical research, where its properties and reactivity are studied to understand its behavior in different chemical reactions. This knowledge aids in the development of novel synthetic routes and methodologies in organic chemistry.

InChI:InChI=1/C9H9NO/c10-8-3-1-2-7-6(8)4-5-9(7)11/h1-3H,4-5,10H2

Upstream product

• 645-45-4 hydrocinnamic acid chloride 
• 34701-14-9 4-nitroindane 
• 83-33-0 inden-1-one 
• 24623-25-4 4-nitro-2,3-dihydro-1H-inden-1-one 
• 24623-24-3 6-nitroindan-1-one 
• 85397-21-3 3-(2-nitro-phenyl)-propionyl chloride 
• 7647-01-0 hydrogenchloride 
• 64-17-5 ethanol 
• 861325-73-7 2,2-dibromo-4-nitro-indan-1-one 

Downstream Products

• 60899-32-3 4-iodo-2,3-dihydro-1H-inden-1-ol 
• 1190482-07-5 6-chloro-N-(1-oxo-2,3-dihydro-1H-inden-4-yl)imidazo[2,1-b][1,3]thiazole-5-sulfonamide 
• 173252-60-3 4-acetamido-2-(2-ethoxycarbonyl-1H-imidazol-1-yl)indanone 

Relevant articles and documents

Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation

Successes have been achieved in developing human monoamine oxidase B (hMAO-B) inhibitors as anti-Parkinson's disease (PD) drugs. However, low efficiency and unwanted side effects of the marketed hMAO-B inhibitors hamper their medical applications, therefore, novel potent selective hMAO-B inhibitors are still of great interest. Herein we report 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as hMAO-B inhibitors, which were designed by employing a fragment-based drug design strategy to link rasagiline to hydrophobic fragments. Among the synthesized 31 compounds, K8 and K24 demonstrated very encouraging hMAO-B inhibitory activities and selectivity over hMAO-A, better than rasagiline and safinamide. In vitro studies indicated that K8 and K24 are nontoxic to nervous tissue cells and they have considerable effects against ROS formation and potential neuroprotective activity. Further mice behavioral tests demonstrated these two compounds have good therapeutic effects on MPTP-induced PD model mice. All these experiment results suggest that compounds K8 and K24 can be promising candidates for further research for treatment of PD.

Synthesis of haloindenes

The subject invention provides an expedited synthesis of 5, 6, and 7-iodoindenes from the corresponding aminoindan-1-ones in more than 70% yield, employing readily available precursors and reagents. A three-step sequence involves diazotization-iodination of aminoindan-1-one followed by reduction and dehydration. The method has a general character and can be extended for the preparation of various 4-, 5-, 6- or 7-haloindenes using different halogen sources for diazotization-halogenation reaction.

Iodoindenes: Synthesis and application to cross-coupling

An expeditious synthesis of 5-, 6-, and 7-iodoindenes from the corresponding aminoindan-1-ones in more than 70% yield employing readily available precursors and ubiquitous reagents is reported. The 4-iodoindene has been prepared analogously in 40% overall yield. A three-step sequence involves diazotization-iodination of aminoindan-1-one followed by the reduction and dehydration. The iodoindenes serve as effective substrates for the regioselective Stille coupling with vinyl stannanes but isomeric mixtures are produced during Sonogashira coupling with alkynes in the presence of triethylamine.

COVALENT TARGETING OF E3 LIGASES

Disclosed herein, inter alia, are compositions and methods for targeting E3 ligases. In an aspect is a targeted protein degrader including 1) a targeted protein binder and 2) an E3 Ubiquitin ligase binder, wherein the E3 Ubiquitin ligase is human RNF4 or human RNF114. In an aspect is provided a pharmaceutical composition including a compound as described herein, including embodiments, and a pharmaceutically acceptable excipient.

METHODS FOR MAKING QUINOLINYLDIAMINES

The present disclosure provides methods for making quinolinyldiamine products from quinolinyl starting materials. In addition, the quinolinyldiamines can be used as ligands or ligand precursors for catalysts, e.g. for use in olefin polymerization.

Discovery of novel 2,3-dihydro-1H-inden-1-amine derivatives as selective monoamine oxidase B inhibitors

Inhibition of MAO-B has been an effective strategy for the treatment of Parkinson's disease. To find more potent and selective MAO-B inhibitors with novel chemical scaffold, we designed and synthesized a series of new 2,3-dihydro-1H-inden-1-amine derivatives on basis of our previous study. Furthermore, the corresponding structure-activity relationship (SAR) of these compounds is detailedly discussed. Compounds L4 (IC50 = 0.11 μM), L8 (IC50 = 0.18 μM), L16 (IC50 = 0.27 μM) and L17 (IC50 = 0.48 μM) showed similar MAO-B inhibitory activity as Selegiline. Moreover, L4, L16 and L17 also exhibited comparable selectivity with Selegiline, indicating that L4, L16 and L17 could be promising selective MAO-B inhibitors for further study.

Sulfonamides having antiangiogenic and anticancer activity

Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.

Cyclopentenoquinolone compounds for treating bacterial infections

Certain novel cyclopentenoquinolone derivatives of the formula: SPC1 Wherein R and X, which may be the same or different, are hydrogen or lower saturated or unsaturated aliphatic hydrocarbyl; Y is hydroxyl or lower alkoxy or lower acyloxy (i.e., alkanoyloxy); and Z is hydrogen or lower alkoxy, or, together with Y, represents an oxo or lower alkenyldioxy radical; and the pharmacologically compatibile salts thereof Are outstandingly effective as anti-microbials, particularly for applications against infections of the urinary tract.